Diabetes mellitus is one of most prevalent disease around the world. The persistent hyperglycemic state is associated with risk of atherosclerosis (myocardial infarction) development1. Important qualities required for diabetes treating drugs is their ability to provide sustained and stable glycemic control and produce a sustained decrease of the HbA1c values, even during long-term treatment.
Dipeptidyl peptidase-4 (DPP-4) inhibitors contribute to glycemic control in diabetes patients2. DPP-4 inhibitors have been predicted to promote insulin secretion through increasing the amount of one of the incretions i.e. active GLP-1 and on the other hand, the possibility has also been suggested that DPP-4 inhibition has effects other than on the blood glucose (BG) level i.e. extra pancreatic effects when treated for long term.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Boehringer Ingelheim (Pharmaceutical Company) for treatment of diabetes mellitus type 2. Researchers conducted a study in which they wanted to clarify the stability of blood glucose control in patients receiving long-term treatment with linagliptin3.
Researchers from Japan lead an experiment; Linagliptin was administered to 25 type 2 diabetes patients for 18 months and assessed for its effects on hemoglobin A1c (HbA1c) and serum lipids. 3 months after the start of linagliptin treatment, the HbA1c of the 13 patients was significantly lowered and its effect continued for 18 months.
Moreover the serum total cholesterol and LDL cholesterol of the patients was also improved. HbA1c significantly increased in the12 patients from 6 months of linagliptin treatment and had no effect on the serum lipids. The HbA1c in patients whose HbA1c decreased with linagliptin was significantly high before treatment compared to the patients whose HbA1c increased after treatment. The effects of linagliptin treatment on HbA1c were associated with baseline HbA1c levels before treatment.
Written by: Rabeeia
Your email address will not be published. Required fields are marked *
26 May, 2019